奈达铂、替加氟联合紫杉醇治疗晚期食管癌的近期疗效观察

Clinical Observation on Combined Chemotherapy with Nedaplatin, Tegafur and Paclitaxel in Advanced Esophageal Carcinoma

目的:观察奈达铂(NDP)、替加氟(Ft-207)联合紫杉醇(PTx)治疗晚期食管癌的近期疗效及安全性。方法:选择2008年3月至2010年6月在我院治疗的65例晚期食管癌患者,应用NDP 20 mg/m2,静脉滴注,第1～3天;Ft～207 500 mg/m2,静脉滴注射,第1～5天;PTx 135～175 mg/m2,静脉滴注,第1天;21天为1个周期,至少2个周期后评价疗效和毒副反应的发生情况。结果:除1例因奈达铂过敏反应停药外,共64例患者完成化疗并可评价疗效。该方案总体有效率(RR)为56.3%,其中完全缓解(CR)3例(占4.7%),部分缓解(PR)33例(占51.6%),病情稳定(SD)17例(占26.6%),另有11例(占17.2%)出现不同程度的疾病进展(PD)。仅1例出现可控制的IV度骨髓抑制。结论:NDP、Ft-207联合PTx对晚期食管癌近期疗效肯定,安全性好,值得临床推广应用。

Objective： To investigate the efficacy and safety of the chemotherapy regimen with nedaplatin, tegafur and paclitaxel in advanced tesophageal carcinoma. Methods： Sixty-five patients with pathologically confirmed advanced esophageal carcinoma admitted in our hospital from March 2008 to June 2010 were chosen, and were treated with three-week intravenous chemotherapy regimen with NDP 20 mg/m2, dl-d3, Ft-207 500 mg/m2, dl-d5, and PTx 135-175mg/m2, dl. A treatment cycle was 28 days. The Efficacy and toxicity were evaluated after at least 2 treatment cycles. Results： In 65 cases, only one patient had to quit for allergic reaction to NDP in the first cycle, the other sixty-four patients were eligible for clinical response evaluation, in which the overall response rate was 57.8%, the com- plete remission rate was 4.7% （n=3）, the partial remission rate was 51.6% （n=33） and the stable rate was 26.6% （n=17）, in addition to 17.2% disease progress （n=l 1）. Only one patient encountered a controllable bone marrow depression of grade IV. Conclusion： The com- bined chemotherapy with PTX, NDP and Ft-207 is effective and safe in advanced esophageal cancer, and is worth of further generaliza- tion.